Biotech hVIVO expanding clinical trial capacity

The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services.

Clinical-trial specialist biotech hVIVO has announced the planned expansion of its life sciences hub in Canary Wharf, London.

Due to a growing demand for its services, the company formerly known as Open Orphan, is building a state-of-the-art facility which will include 50 quarantine beds, with potential to expand to 70 beds, and virology and immunology labs.

There will also be an outpatient unit to facilitate phase two and three clinical trials.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO